Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY B HAMMER

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1396885455
CMS profile
944088
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,125.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Edwards Lifesciences Corporation $1,125.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY B HAMMER

NPI 1396885455 · CMS profile ID 944088

Allopathic & Osteopathic Physicians / Anesthesiology

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396885455?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY B HAMMER, NPI 1396885455, CMS profile ID 944088. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396885455?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GREGORY B HAMMER, NPI 1396885455, CMS profile ID 944088. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396885455?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GREGORY B HAMMER, NPI 1396885455, CMS profile ID 944088, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1396885455?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $1,125.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Edwards Lifesciences Corporation $1,125.0003/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023076409 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,777.27 8
PY2020 $2,500.00 2
PY2021 $7,900.36 5
PY2022 $1,125.00 1
PY2023 $1,125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $13,296.00 3
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $192,152.84 3
PY2022 Recipient $330.00 1
PY2022 Principal investigator $406,381.59 42
PY2021 Recipient $4,000.00 1
PY2021 Principal investigator $395,644.11 30
PY2020 Principal investigator $261,247.84 61
PY2019 Principal investigator $566,446.06 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,415.04 12/15/2020 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior University
A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH PROPOFOL PRO ADMINISTERED AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS No dispute reported 06/30/2026 742894083
Principal investigator 1 Merck Sharp & Dohme Corporation $933.12 11/25/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740753709
Principal investigator 1 Merck Sharp & Dohme Corporation $11,548.00 11/19/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740753707
Principal investigator 1 Merck Sharp & Dohme Corporation $9,856.00 11/19/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740753711
Principal investigator 1 PFIZER INC. $9,600.00 11/18/2020 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior University
A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH PROPOFOL PRO ADMINISTERED AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS No dispute reported 06/30/2026 742902603
Principal investigator 1 PFIZER INC. $420.00 11/17/2020 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH PROPOFOL PRO ADMINISTERED AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS No dispute reported 06/30/2026 742859059
Principal investigator 1 PFIZER INC. $420.00 11/11/2020 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH PROPOFOL PRO ADMINISTERED AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS No dispute reported 06/30/2026 742859347
Principal investigator 1 Merck Sharp & Dohme Corporation $2,780.00 11/02/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791201
Principal investigator 1 Merck Sharp & Dohme Corporation $48,563.16 10/29/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754409
Principal investigator 1 Merck Sharp & Dohme Corporation $2,718.00 10/14/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791199
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 10/13/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754383
Principal investigator 1 PFIZER INC. $420.00 10/13/2020 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH PROPOFOL PRO ADMINISTERED AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS No dispute reported 06/30/2026 742859055
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 10/09/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791197
Principal investigator 1 Merck Sharp & Dohme Corporation $19,222.20 10/01/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791195
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 09/29/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754379
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 09/29/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754381
Principal investigator 1 Merck Sharp & Dohme Corporation $2,165.00 09/18/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791157
Principal investigator 1 PFIZER INC. $3,456.00 09/18/2020 Non-covered Recipient Entity
The Board of Trustees of the Leland Stanford Junior University
A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH PROPOFOL PRO ADMINISTERED AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS 1 MONTH TO 17 YEARS OF AGE UNDERGOING MRI SCANS No dispute reported 06/30/2026 742902599
Principal investigator 1 Merck Sharp & Dohme Corporation $920.00 09/16/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791155
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 09/16/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791159
Principal investigator 1 Merck Sharp & Dohme Corporation $6.60 09/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754411
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 09/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754413
Principal investigator 1 Merck Sharp & Dohme Corporation $29.10 09/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754415
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 09/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754417
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 09/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754419
Principal investigator 1 Merck Sharp & Dohme Corporation $16,498.76 08/20/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754347
Principal investigator 1 Hikma Pharmaceuticals USA $11,967.60 05/08/2020 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 717234199
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 05/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754373
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 05/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754375
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 05/08/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754377
Principal investigator 1 Masimo Corporation $655.00 05/07/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer / Stanford / SpO2 No dispute reported 06/30/2026 752185133
Principal investigator 1 Masimo Corporation $2,560.00 04/16/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer / Stanford / SpO2 No dispute reported 06/30/2026 752185123
Principal investigator 1 Masimo Corporation $2,560.00 04/16/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer / Stanford / SpO2 No dispute reported 06/30/2026 752185135
Principal investigator 1 Masimo Corporation $2,560.00 04/16/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer / Stanford / SpO2 No dispute reported 06/30/2026 752185139
Principal investigator 1 Pacira Pharmaceuticals Incorporated $14,067.20 04/14/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930981
Principal investigator 1 Merck Sharp & Dohme Corporation $63.96 04/02/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740753713
Principal investigator 1 Merck Sharp & Dohme Corporation $87.60 04/02/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740753715
Principal investigator 1 Masimo Corporation $4,680.00 03/30/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer / Stanford / SpO2 No dispute reported 06/30/2026 752185141
Principal investigator 1 Merck Sharp & Dohme Corporation $7,455.00 03/27/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791151
Principal investigator 1 Masimo Corporation $655.00 03/19/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer / Stanford / SpO2 No dispute reported 06/30/2026 752185121
Principal investigator 1 Merck Sharp & Dohme Corporation $3,254.35 03/19/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754343
Principal investigator 1 Hikma Pharmaceuticals USA $8,324.00 03/06/2020 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 717234187
Principal investigator 1 Merck Sharp & Dohme Corporation $5,480.00 03/02/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791149
Principal investigator 1 Merck Sharp & Dohme Corporation $5,480.00 03/02/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791153
Principal investigator 1 Merck Sharp & Dohme Corporation $1,920.00 02/24/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791111
Principal investigator 1 Merck Sharp & Dohme Corporation $14,069.00 02/18/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754341
Principal investigator 1 Hikma Pharmaceuticals USA $1,000.00 02/07/2020 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 717234185
Principal investigator 1 Pacira Pharmaceuticals Incorporated $750.00 01/31/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930909
Principal investigator 1 Pacira Pharmaceuticals Incorporated $889.60 01/31/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930911
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,765.12 01/31/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930913
Principal investigator 1 Pacira Pharmaceuticals Incorporated $2,860.80 01/31/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930915
Principal investigator 1 Pacira Pharmaceuticals Incorporated $2,688.00 01/31/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930917
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,420.80 01/31/2020 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) No dispute reported 06/30/2026 747930919
Principal investigator 1 Merck Sharp & Dohme Corporation $1,564.00 01/29/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791109
Principal investigator 1 Merck Sharp & Dohme Corporation $23,769.60 01/24/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 740791113
Principal investigator 1 Merck Sharp & Dohme Corporation $1,347.40 01/23/2020 Non-covered Recipient Entity
LUCILLE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 740754345
Principal investigator 1 Merck Sharp & Dohme Corporation $0.96 01/09/2020 Non-covered Recipient Entity
STANFORD UNIV SCHOOL OF MED
Development and Feasibility of a Scale to Assess Postoperative Recovery The Post-operative Quality Recovery Scale No dispute reported 06/30/2026 740770643
Principal investigator 1 Merck Sharp & Dohme Corporation $23.28 01/09/2020 Non-covered Recipient Entity
STANFORD UNIV SCHOOL OF MED
Development and Feasibility of a Scale to Assess Postoperative Recovery The Post-operative Quality Recovery Scale No dispute reported 06/30/2026 740770645
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 01/09/2020 Non-covered Recipient Entity
STANFORD UNIV SCHOOL OF MED
Development and Feasibility of a Scale to Assess Postoperative Recovery The Post-operative Quality Recovery Scale No dispute reported 06/30/2026 740770647
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 01/09/2020 Non-covered Recipient Entity
STANFORD UNIV SCHOOL OF MED
Development and Feasibility of a Scale to Assess Postoperative Recovery The Post-operative Quality Recovery Scale No dispute reported 06/30/2026 740770649
Principal investigator 1 Merck Sharp & Dohme Corporation $5.28 01/09/2020 Non-covered Recipient Entity
STANFORD UNIV SCHOOL OF MED
Development and Feasibility of a Scale to Assess Postoperative Recovery The Post-operative Quality Recovery Scale No dispute reported 06/30/2026 740770651